UY31408A1 - "productos quimioterapéuticos cristalinos" - Google Patents

"productos quimioterapéuticos cristalinos"

Info

Publication number
UY31408A1
UY31408A1 UY31408A UY31408A UY31408A1 UY 31408 A1 UY31408 A1 UY 31408A1 UY 31408 A UY31408 A UY 31408A UY 31408 A UY31408 A UY 31408A UY 31408 A1 UY31408 A1 UY 31408A1
Authority
UY
Uruguay
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
3amino
Prior art date
Application number
UY31408A
Other languages
English (en)
Inventor
Rodger F Henry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40174825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31408(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31408A1 publication Critical patent/UY31408A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Forma cristalina 1 de etanolato de N-[4-3amino-1H-indazol-4-il)fenil]- N-(2-fluoro-5-metilfenil)urea L, formas de elaborarla, formulaciones que la comprenden y elaboradas con la misma y métodos que la utilizan para el tratamiento de pacientes enfermos.
UY31408A 2007-10-19 2008-10-17 "productos quimioterapéuticos cristalinos" UY31408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98131007P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
UY31408A1 true UY31408A1 (es) 2009-05-29

Family

ID=40174825

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31408A UY31408A1 (es) 2007-10-19 2008-10-17 "productos quimioterapéuticos cristalinos"

Country Status (25)

Country Link
US (1) US7994208B2 (es)
EP (1) EP2195300B1 (es)
JP (2) JP5878689B2 (es)
KR (1) KR20100085986A (es)
CN (1) CN101827821B (es)
AR (1) AR068918A1 (es)
AU (1) AU2008312528A1 (es)
BR (1) BRPI0818067A2 (es)
CA (1) CA2699302C (es)
CL (1) CL2008003091A1 (es)
CO (1) CO6280482A2 (es)
CR (1) CR11387A (es)
DO (1) DOP2010000113A (es)
EC (1) ECSP10010182A (es)
ES (1) ES2547878T3 (es)
GT (1) GT201000093A (es)
MX (1) MX2010004288A (es)
PA (1) PA8800301A1 (es)
PE (1) PE20091075A1 (es)
RU (1) RU2010119927A (es)
TW (1) TW200932728A (es)
UA (1) UA99747C2 (es)
UY (1) UY31408A1 (es)
WO (1) WO2009052225A1 (es)
ZA (1) ZA201002180B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US20140212355A1 (en) * 2013-01-28 2014-07-31 Abbott Cardiovascular Systems Inc. Trans-arterial drug delivery
JP7346916B2 (ja) * 2019-06-04 2023-09-20 京セラドキュメントソリューションズ株式会社 緩衝構造体およびそれを備えた包装材

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
SI1638941T1 (sl) * 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20070104780A1 (en) 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
AR068918A1 (es) 2009-12-16
US20090105326A1 (en) 2009-04-23
JP2011500704A (ja) 2011-01-06
CA2699302C (en) 2016-06-21
US7994208B2 (en) 2011-08-09
CN101827821A (zh) 2010-09-08
PA8800301A1 (es) 2009-08-26
ECSP10010182A (es) 2010-06-29
CA2699302A1 (en) 2009-04-23
MX2010004288A (es) 2010-04-30
AU2008312528A1 (en) 2009-04-23
CN101827821B (zh) 2012-09-05
EP2195300A1 (en) 2010-06-16
CR11387A (es) 2010-08-18
RU2010119927A (ru) 2011-11-27
PE20091075A1 (es) 2009-08-27
BRPI0818067A2 (pt) 2015-03-31
ZA201002180B (en) 2011-10-26
JP5878689B2 (ja) 2016-03-08
UA99747C2 (en) 2012-09-25
EP2195300B1 (en) 2015-06-24
JP2015042650A (ja) 2015-03-05
CO6280482A2 (es) 2011-05-20
GT201000093A (es) 2012-03-12
DOP2010000113A (es) 2010-07-31
TW200932728A (en) 2009-08-01
KR20100085986A (ko) 2010-07-29
WO2009052225A1 (en) 2009-04-23
CL2008003091A1 (es) 2009-09-04
ES2547878T3 (es) 2015-10-09

Similar Documents

Publication Publication Date Title
CR20140576A (es) Sintesis de compuestos heterociclicos
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
RS54642B1 (en) MEGLUMIN SO 6-FLUOR-3-HYDROXY-2-PYRAZINE CARBOXAMIDE
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
CL2007001779A1 (es) Compuestos triciclicos, con afinidad superior por los receptores de melatonina; composicion farmaceutica; util para la profilaxis o tratamiento de la enfermedad del sueno y compuestos intermediarios.
UY31408A1 (es) "productos quimioterapéuticos cristalinos"
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
DK2155179T3 (da) Axomadol til smertebehandling arthrose
MY145139A (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
GT200600141A (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
ECSP10010188A (es) Productos quimioterapéuticos cristalinos derivados de indazol
CL2009000496A1 (es) Formas cristalina tipo iii de (3,5-bis trifluorometil)-n-[4-metil-3-(4-piridin-3-il)-pirimidin-2-ilamino)-fenil]-benzamida; proceso de preparacion de la forma cristalina iii; composion farmaceutica que compende la forma cristalina iii; y su uso como agente antitumoral.
AR063895A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171017